Moffitt Cancer Center | Strategic Alliance Partners

June 24, 2022

Robert Wenham, MD, MS, FACOG, FACS, discusses the current treatment landscape for patients with cervical and endometrial cancers, ADCs and PARP inhibitors in ovarian cancer, advancements in HER2-positive breast cancer, and surgical options for patients with ovarian cancer.

June 20, 2022

Robert Wenham, MD, MS, FACOG, FACS, discusses the role of antibody-drug conjugates in ovarian cancer.

May 31, 2022

David Sallman, MD, discusses the background of the menin inhibitor, KO-539, in acute myeloid leukemia.

May 19, 2022

Developing a system with a patient-centric focus, investigators at Yale Cancer Center and Moffitt Cancer Center initiated pilot programs to offer patients better access to care following a diagnosis of cancer.

May 16, 2022

Data from a retrospective analysis demonstrated that mitomycin gel was safe and effective when administered using an antegrade approach in real-world populations of patients with low-grade upper tract urothelial cancer.

May 15, 2022

Philippe E. Spiess, MD, MS, FACS, shares key updates in the management of patients with penile cancer.

May 12, 2022

Bijal Shah, MD, MS, discusses the results of a phase 2 pilot study investigating CPX-351 in adults with high-risk relapsed/refractory acute lymphoblastic leukemia, as well as next steps for research in this patient population.

May 04, 2022

The safety and efficacy of the combination of the oncolytic immunotherapy CG0070 and nivolumab is under exploration as a potential therapeutic option in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy, as part of the phase 1b CORE-002 trial.

April 28, 2022

An investigative follicle-stimulating hormone receptor–mediated CAR T-cell technology is under exploration in patients with recurrent ovarian cancer.

April 26, 2022

Oncolytic immunotherapy with talimogene laherparepvec and vusolimogene oderparepvec has the potential to provide unique clinical benefits in patients with melanoma through direct intratumoral administration.

April 22, 2022

Nikhil Khushalani, MD, discusses the mechanism of action vusolimogene oderparepvec in cancer care.

March 30, 2022

David Sallman, MD, discusses the examination of magrolimab in acute myeloid leukemia.

March 28, 2022

In acute myeloid leukemia, investigators are exploring novel agents engineered to target adhesion factors, which can mobilize persistent leukemic stem cells from the bone marrow niche.

March 23, 2022

David Sallman, MD, provides perspective on the novel agent uproleselan, its efficacy in a phase 1/2 trial, and its investigation in phase 3 trials in acute myeloid leukemia.

March 21, 2022

Philippe E. Spiess, MD, MS, FACS, discusses the rationale for investigating the MTAP pathway in genitourinary cancers.

March 21, 2022

Frederick Locke, MD, discusses the phase 3 ZUMA-7 trial examining axicabtagene ciloleucel in the second-line treatment of patients with relapsed/refractory large B-cell lymphoma, safety and efficacy findings with the therapy, and the significance of the data that have been reported to date.

March 16, 2022

David Sallman, MD, discusses the role of uproleselan (GMI-1271) when utilized in acute myeloid leukemia.

February 16, 2022

Zeynep Eroglu, MD, discusses the potential of ctDNA as a noninvasive biomarker in melanoma, outlines different assays under development, and details potential opportunities to leverage ctDNA in treatment decision making.

January 10, 2022

David Sallman, MD, discusses responses achieved a first-in-human dose escalation/dose expansion phase 1/1b clinical trial of an UltraCAR-T agent, PRGN-3006, in patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome with hypomethylating agent failure.

December 13, 2021

Axicabtagene ciloleucel demonstrated favorable efficacy in elderly patients and those with other comorbidities with large B-cell lymphoma; however, adverse events were more common in some of these populations and ECOG performance status ≥2 was associated with worse outcomes and more adverse events, according to a large real-world study presented at the 2021 ASH Annual Meeting.